 Translate Bio Inc NASDAQ: TBIO has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia PCD. Mutations in the genes that cause PCD result in ineffective mucociliary clearance, which can lead to lung disease. 